Literature DB >> 11979370

Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate.

Mar Royuela1, Maria Isabel Arenas, Fermin R Bethencourt, Manuel Sánchez-Chapado, Benito Fraile, Ricardo Paniagua.   

Abstract

This study investigate the expression of the mitogen-activated protein kinases (MAPKs) in normal prostate, benign prostatic hyperplasia (BPH), and prostatic cancer (PC), and also the possible relationship between the activity of these MAPKs and the apoptosis/proliferation index. Immunochemical techniques were carried out using 2 mouse monoclonal antibodies against human extracellular signal-regulated protein kinase (ERK) and Jun N-terminal kinase (JNK), and 1 goat polyclonal antibody against mouse p38. To compare the results obtained in the 3 specimens, the average percentages of both epithelial and stromal immunostained cells were calculated on immunostained sections. For each of the 3 kinases studied, the percentage of immunostained stromal cells did not change with prostatic alterations. For both ERK and p38, the percentage of immunostained epithelial cells increased significantly in BPH and even more so in PC. For JNK, the percentage of immunostained epithelial cells increased significantly only in PC. These results suggest that ERK could be involved in the elevated proliferation indexes reported in BPH and PC, whereas p38 might contribute to the increased apoptotic index reported in PC. The most probable action of JNK in PC would be cell proliferation stimulation. Overexpression of MAPKs, involved in the development of prostatic hyperplasia and neoplasia, might be secondary to the overexpression of several growth factors. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979370     DOI: 10.1053/hupa.2002.32227

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  23 in total

1.  Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3.

Authors:  F Strittmatter; S Walther; C Gratzke; J Göttinger; C Beckmann; A Roosen; B Schlenker; P Hedlund; K E Andersson; C G Stief; M Hennenberg
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma.

Authors:  L Zhuang; C S Lee; R A Scolyer; S W McCarthy; A A Palmer; X D Zhang; J F Thompson; L P Bron; P Hersey
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

Review 3.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

4.  The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells.

Authors:  Seung-Keun Hong; Jin-Hwan Kim; Ming-Fong Lin; Jong-In Park
Journal:  Exp Cell Res       Date:  2011-08-16       Impact factor: 3.905

5.  AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion.

Authors:  Seung-Keun Hong; Joseph H Jeong; Andrew M Chan; Jong-In Park
Journal:  Exp Cell Res       Date:  2013-05-20       Impact factor: 3.905

Review 6.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors.

Authors:  Hari K Koul; Mantu Pal; Sweaty Koul
Journal:  Genes Cancer       Date:  2013-09

7.  A role for STEAP2 in prostate cancer progression.

Authors:  Helen Whiteland; Samantha Spencer-Harty; Claire Morgan; Howard Kynaston; David Hywel Thomas; Pradeep Bose; Neil Fenn; Paul Lewis; Spencer Jenkins; Shareen H Doak
Journal:  Clin Exp Metastasis       Date:  2014-09-24       Impact factor: 5.150

Review 8.  [Pathophysiology and therapy of benign prostatic hyperplasia].

Authors:  Natalie Sampson; Stephan Madersbacher; Peter Berger
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

9.  Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation.

Authors:  Li-ping Yang; Xiu-an Zhu; Mark O M Tso
Journal:  Mol Vis       Date:  2007-07-09       Impact factor: 2.367

10.  Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate.

Authors:  Gonzalo Rodríguez-Berriguete; Benito Fraile; Fermín R de Bethencourt; Angela Prieto-Folgado; Nahikari Bartolome; Claudia Nuñez; Bruna Prati; Pilar Martínez-Onsurbe; Gabriel Olmedilla; Ricardo Paniagua; Mar Royuela
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.